Cargando…
WP1130 attenuates cisplatin resistance by decreasing P53 expression in non–small cell lung carcinomas
Cisplatin-based combination chemotherapy significantly improves the survival outcomes in non–small cell lung carcinomas (NSCLCs), but drug resistance commonly contributes to disease progression and relapse. Recently, accumulating evidence has indicated that deubiquitinases (DUBs) are involved in reg...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Impact Journals LLC
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564746/ https://www.ncbi.nlm.nih.gov/pubmed/28446729 http://dx.doi.org/10.18632/oncotarget.16931 |